Bank of New York Mellon Corp reduced its stake in shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) by 13.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 74,011 shares of the biopharmaceutical company’s stock after selling 11,845 shares during the quarter. Bank of New York Mellon Corp owned 0.07% of AVEO Pharmaceuticals worth $164,000 as of its most recent SEC filing.

Separately, Paloma Partners Management Co acquired a new stake in shares of AVEO Pharmaceuticals during the 1st quarter worth $184,000. Institutional investors own 53.93% of the company’s stock.

Shares of AVEO Pharmaceuticals, Inc. (AVEO) opened at $3.21 on Monday. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of -0.83. AVEO Pharmaceuticals, Inc. has a 12 month low of $0.50 and a 12 month high of $4.24.

WARNING: “Bank of New York Mellon Corp Has $164,000 Stake in AVEO Pharmaceuticals, Inc. (AVEO)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-has-164000-stake-in-aveo-pharmaceuticals-inc-aveo/1681869.html.

Several analysts have recently issued reports on the company. BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Monday, July 24th. FBR & Co reissued an “outperform” rating and set a $3.00 target price on shares of AVEO Pharmaceuticals in a report on Thursday, July 13th. Piper Jaffray Companies increased their target price on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a report on Monday, August 28th. Finally, Seaport Global Securities reissued a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $3.42.

AVEO Pharmaceuticals Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.